D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections

Abstract The excessive use of antifungal agents, compounded by the shortage of new drugs being introduced into the market, is causing the accumulation of multi-resistance phenotypes in many fungal strains. Consequently, new alternative molecules to conventional antifungal agents are urgently needed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pauline Dartevelle, Claire Ehlinger, Abdurraouf Zaet, Christian Boehler, Morgane Rabineau, Benoit Westermann, Jean-Marc Strub, Sarah Cianferani, Youssef Haïkel, Marie-Hélène Metz-Boutigue, Céline Marban
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6542be9b5ef34063b0fd3b1f1dd72f6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6542be9b5ef34063b0fd3b1f1dd72f6f
record_format	dspace
spelling	oai:doaj.org-article:6542be9b5ef34063b0fd3b1f1dd72f6f2021-12-02T15:07:50ZD-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections10.1038/s41598-018-27417-x2045-2322https://doaj.org/article/6542be9b5ef34063b0fd3b1f1dd72f6f2018-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-27417-xhttps://doaj.org/toc/2045-2322Abstract The excessive use of antifungal agents, compounded by the shortage of new drugs being introduced into the market, is causing the accumulation of multi-resistance phenotypes in many fungal strains. Consequently, new alternative molecules to conventional antifungal agents are urgently needed to prevent the emergence of fungal resistance. In this context, Cateslytin (Ctl), a natural peptide derived from the processing of Chromogranin A, has already been described as an effective antimicrobial agent against several pathogens including Candida albicans. In the present study, we compared the antimicrobial activity of two conformations of Ctl, L-Ctl and D-Ctl against Candida albicans. Our results show that both D-Ctl and L-Ctl were potent and safe antifungal agents. However, in contrast to L-Ctl, D-Ctl was not degraded by proteases secreted by Candida albicans and was also stable in saliva. Using video microscopy, we also demonstrated that D-Ctl can rapidly enter C. albicans, but is unable to spread within a yeast colony unless from a mother cell to a daughter cell during cellular division. Besides, we revealed that the antifungal activity of D-Ctl could be synergized by voriconazole, an antifungal of reference in the treatment of Candida albicans related infections. In conclusion, D-Ctl can be considered as an effective, safe and stable antifungal and could be used alone or in a combination therapy with voriconazole to treat Candida albicans related diseases including oral candidosis.Pauline DartevelleClaire EhlingerAbdurraouf ZaetChristian BoehlerMorgane RabineauBenoit WestermannJean-Marc StrubSarah CianferaniYoussef HaïkelMarie-Hélène Metz-BoutigueCéline MarbanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pauline Dartevelle Claire Ehlinger Abdurraouf Zaet Christian Boehler Morgane Rabineau Benoit Westermann Jean-Marc Strub Sarah Cianferani Youssef Haïkel Marie-Hélène Metz-Boutigue Céline Marban D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections
description	Abstract The excessive use of antifungal agents, compounded by the shortage of new drugs being introduced into the market, is causing the accumulation of multi-resistance phenotypes in many fungal strains. Consequently, new alternative molecules to conventional antifungal agents are urgently needed to prevent the emergence of fungal resistance. In this context, Cateslytin (Ctl), a natural peptide derived from the processing of Chromogranin A, has already been described as an effective antimicrobial agent against several pathogens including Candida albicans. In the present study, we compared the antimicrobial activity of two conformations of Ctl, L-Ctl and D-Ctl against Candida albicans. Our results show that both D-Ctl and L-Ctl were potent and safe antifungal agents. However, in contrast to L-Ctl, D-Ctl was not degraded by proteases secreted by Candida albicans and was also stable in saliva. Using video microscopy, we also demonstrated that D-Ctl can rapidly enter C. albicans, but is unable to spread within a yeast colony unless from a mother cell to a daughter cell during cellular division. Besides, we revealed that the antifungal activity of D-Ctl could be synergized by voriconazole, an antifungal of reference in the treatment of Candida albicans related infections. In conclusion, D-Ctl can be considered as an effective, safe and stable antifungal and could be used alone or in a combination therapy with voriconazole to treat Candida albicans related diseases including oral candidosis.
format	article
author	Pauline Dartevelle Claire Ehlinger Abdurraouf Zaet Christian Boehler Morgane Rabineau Benoit Westermann Jean-Marc Strub Sarah Cianferani Youssef Haïkel Marie-Hélène Metz-Boutigue Céline Marban
author_facet	Pauline Dartevelle Claire Ehlinger Abdurraouf Zaet Christian Boehler Morgane Rabineau Benoit Westermann Jean-Marc Strub Sarah Cianferani Youssef Haïkel Marie-Hélène Metz-Boutigue Céline Marban
author_sort	Pauline Dartevelle
title	D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections
title_short	D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections
title_full	D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections
title_fullStr	D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections
title_full_unstemmed	D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections
title_sort	d-cateslytin: a new antifungal agent for the treatment of oral candida albicans associated infections
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/6542be9b5ef34063b0fd3b1f1dd72f6f
work_keys_str_mv	AT paulinedartevelle dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT claireehlinger dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT abdurraoufzaet dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT christianboehler dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT morganerabineau dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT benoitwestermann dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT jeanmarcstrub dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT sarahcianferani dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT youssefhaikel dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT mariehelenemetzboutigue dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections AT celinemarban dcateslytinanewantifungalagentforthetreatmentoforalcandidaalbicansassociatedinfections
_version_	1718388391376060416

D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections

Ejemplares similares